Wegovy

Eli Lilly's drug, Foundayo, has won approval in the U.K., extending its participation in the weight-loss pill battle beyond the U.S. market. This development intensifies the competition between Eli Lilly and Novo Nordisk regarding their respective treatments.

Bank of America spends $250 million annually on GLP-1 drugs for its employees, according to the CEO. Employers face challenges due to rising demand for costly GLP-1 medications like Ozempic and Wegovy.

Novo Nordisk Chief Executive Officer Mike Doustdar states that the profitability of its weight-loss pill Wegovy is 'decent' and will improve, citing expansion into more markets as evidence. He emphasizes that continued market launches support this outlook.

Novo Nordisk CEO Mike Doustdar stated the company is not currently discussing further discounts for its Wegovy weight-loss pill, which underperformed sales expectations and disappointed investors.

Novo Nordisk stock is declining due to the underperformance of its Wegovy pill, though the company reported an improved annual outlook. The Danish drugmaker attributed the stock slide partly to the pill's unexpected results.

A study by Rutgers University researchers suggests GLP-1 weight-loss drugs like Ozempic and Wegovy may reduce links between impulsivity, alcohol use, and violent behavior. The research found associations between impulsivity and violence were 62% weaker among current users compared to former users, while alcohol-related violence was 52% weaker.

Novo Nordisk is raising its full-year outlook due to strong sales of its weight loss pill Wegovy, which has surpassed 5 million prescriptions in the U.S., driving higher-than-expected profits.

The human brain evolved to protect body fat during scarcity, treating a higher weight as normal and triggering hunger and lower energy use after weight loss. Medications like Wegovy and Mounjaro can reduce appetite signals, though their effects may diminish when treatment stops.

Walmart, Costco, and Amazon are competing to provide direct-to-consumer access to weight loss drugs like Wegovy and Zepbound as employers reduce coverage for these medications.

Patients taking GLP-1 medications like Ozempic, Wegovy, or Zepbound may need extended fasting or adjusted care before surgery due to slowed stomach emptying, which increases aspiration risk under anesthesia. Physician anesthesiologists require detailed medication information to ensure safe procedures, though most patients undergo surgery without complications.

The author, Rachel Varina, discusses how starting Wegovy, a GLP-1 medication, transformed her travel habits by reducing food cravings and altering her approach to dining. She now prioritizes experiences over meals, packs snacks to manage appetite, and emphasizes hydration due to side effects like nausea and diarrhea.

Employers are reducing coverage for GLP-1 medications like Ozempic and Wegovy to cut healthcare costs, but a study suggests this may backfire. Research from the National Bureau of Economic Research found GLP-1 treatments reduced long-term sick leave by 17.3% and generated $866 in annual productivity gains per worker in Denmark. However, U.S. employers face different healthcare systems and higher costs, complicating direct comparisons.

A growing trend of microdosing GLP-1 drugs like Ozempic and Wegovy is spreading via social media, with users altering doses to reduce costs and side effects. However, this practice lacks FDA approval and clinical testing, posing unpredictable health risks. Pharmacist Sue Ojageer warns that self-directed microdosing bypasses medical supervision and may not be safer than standard prescriptions.

A person reported minimal weight loss while using Wegovy and Mounjaro alongside restricted eating, spending £4,000 without success. They expressed regret for not trying an unnamed effective diet plan earlier.

Novo Nordisk is requesting a court to block Eli Lilly's advertisements for Zepbound and Mounjaro, alleging the ads use outdated data and fail to mention newer, higher-dose versions of Wegovy and Ozempic.

Australia’s Therapeutic Goods Administration (TGA) has issued warnings for diabetes and weight loss drugs like Ozempic, Wegovy, and Mounjaro, linking them to 36 cases of a rare but severe eye disorder called NAION that could cause blindness. The TGA updated product information to include this health risk.

Eli Lilly's obesity drug retatrutide showed significant weight loss in a Phase 3 study but did not reduce cardiovascular risk. The U.S. Medicare program is offering injectable GLP-1 obesity medications like Wegovy, Foundayo, and Zepbound through a trial program for $50 monthly, with high patient demand for injectables despite expectations of pill preference.

A ReturnPro survey indicates GLP-1 medications like Ozempic and Wegovy are altering clothing shopping habits in the U.S., with 71% of users buying more apparel due to changing sizes and 65% purchasing multiple sizes for returns. Men were nearly twice as likely as women to buy multiple sizes for returns, while psychological factors linked to the drugs may drive spending shifts toward clothing and wellness.

Novo Nordisk sued Eli Lilly for misleading advertising in the US weight-loss drug market, alleging outdated weight-loss comparisons. Novo also previously sued Hims & Hers over a copycat version of Wegovy. The dispute highlights differences in global advertising regulations, as most countries prohibit ads for prescription-only medications.

A federal CMS pilot program offers limited coverage of three GLP-1 weight-management medications for qualifying Metro Nashville retirees on Medicare or Medicare Advantage. The program, separate from Metro’s health plan, requires a $50 monthly copay and mandates prescriptions be processed through a CMS system, not Metro’s plan. Vanderbilt University is studying the drugs’ potential for asthma and obesity.

Novo Nordisk sued Eli Lilly, alleging deceptive advertising claims about its weight-loss drug Zepbound compared to Novo Nordisk's Wegovy. The lawsuit claims Eli Lilly's ads use outdated clinical trials comparing different doses and mislead consumers into believing Zepbound is superior. Eli Lilly has defended its advertising and intends to contest the lawsuit.

Novo Nordisk sued Eli Lilly over claims that its weight-loss medications work better than Novo's, alleging deceptive advertising with outdated trials. The lawsuit, filed in New Jersey, accuses Lilly of comparing high doses of Zepbound to lower doses of Wegovy and Ozempic. Novo seeks a court order to stop the ads and a correction campaign, with a potential preliminary injunction if compliance is not voluntary.

Novo Nordisk sued Eli Lilly for allegedly running a deceptive ad campaign using outdated clinical trials to compare higher doses of its drugs Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic. The lawsuit, filed in New Jersey federal court, accuses Lilly of intentionally confusing consumers through misleading advertising.

Novo Nordisk promotes LifeMD as a provider for GLP-1 drugs, but former employees allege the telehealth company prioritized profits over patient safety by pressuring providers to rapidly issue prescriptions without thorough clinical review. Ex-workers reported providers were sometimes required to process 25 patient cases per hour, with limited time spent per case and discouragement of medically relevant questions.

The article provides expert tips for rapid weight loss without using the Wegovy pill, aiming to help readers overcome diet plateaus and achieve significant weight loss before summer.

Doctors warn that Ozempic and Wegovy may pose a hidden danger for users with brain disorders. The article notes that weight loss from these medications could accelerate ALS progression in patients.

Neurologists warn that GLP-1 agonists like Ozempic and Wegovy, which promote rapid weight loss, may worsen neurodegenerative conditions such as ALS by accelerating physical decline. A case report shows an ALS patient’s condition deteriorated after using semaglutide, stabilizing only after discontinuation.

U.S. wholesale prices fell 0.3% in June due to declining energy costs, though annual inflation remains above the Fed’s 2% target. TikTok Shop’s rise in AI-generated product videos raises concerns about authenticity and fair competition. GLP-1 medication users may experience cyclosporiasis symptoms differently, complicating diagnosis during an ongoing outbreak.

Biogen's experimental Alzheimer's drug diranersen showed slowed cognitive decline in a mid-stage trial, prompting a potential Phase 3 trial. A study highlighted potential frailty risks in older adults using Eli Lilly's Zepbound and Novo Nordisk's Wegovy, urging closer monitoring for seniors.

Vivani Medical is developing an implant containing semaglutide, the active ingredient in Novo Nordisk's obesity treatment Wegovy and diabetes drug Ozempic, as a new approach to help patients maintain weight loss.

Poison control calls involving semaglutide (Ozempic and Wegovy) increased significantly after the drug's approval for weight management. Researchers attribute the rise to accidental dosing errors rather than intentional misuse, suggesting education on proper weekly dosing and gradual dose increases could prevent many incidents.

The use of GLP-1 drugs like Wegovy for weight loss in the US has increased from 3% to 11% in 2024, with an additional 4% reporting past use, per Gallup polling. Obesity rates in the US fell to 36.4% in 2024 from a peak of 39.9% in 2022, and early research suggests these drugs may offer benefits beyond weight loss, including treating alcohol abuse and reducing coronary disease risk.

A new daily Wegovy pill is now available from online pharmacies at £60 a month. Asda reports thousands have already ordered the first-of-its-kind drug.

Sales of fat-loss drugs in India have slowed after an initial surge driven by generic versions of semaglutide-based medications. Semaglutide is the active ingredient in Novo Nordisk’s Ozempic and Wegovy.

The weight loss pill Wegovy is now available in the UK. The article provides key information about its availability.

A new daily Wegovy pill is launching in UK pharmacies today, with the article listing UK prices for the weight-loss tablet. The product is marketed as a convenient alternative to the existing Wegovy treatment.

The Wegovy weight loss pill, developed by the makers of the Wegovy weight-loss jab, is now available for private purchase in UK pharmacies. It is a once-a-day pill option for weight management.

The UK drugs watchdog has announced that thousands of people with liver disease will be prescribed the weight-loss medication Wegovy. The decision aims to address the condition through a treatment that reduces weight, which is linked to liver health.

Wegovy weight-loss pills are now available at Superdrug for £79. Superdrug has become the first high street pharmacy to launch these tablets.

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.